Ambrx to supply Sino Bio with two next-gen biologics

US-based biotech Ambrx Inc., is set to supply China’s Sino Biopharmaceutical Ltd (1177.HK) with two next-generation biologic drug candidates under a license deal. Under the collaboration, Ambrx has already received an upfront payment to create two innovative candidates using its non-natural amino acid incorporation technology platforms. Sino Bio has also agreed to further milestone payments and royalties on any future sales, with details not disclosed.

The deal will lead to a close collaboration between the two firms. Sino Bio will lead IND enabling activities for both China and the US, while global development will be guided jointly. Sino Bio will commercialize resulting products in Greater China, while Ambrx will retain commercial rights for the rest of the world. The San Diego-based Ambrx is owned by Chinese investors, and aims to produce best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates, using its Protein Medicinal Chemistry platform.


Related news
Agilent Technologies (NYSE: A) announced that the National Medical Products Administration (NMPA) approved its Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) System for use in China.
Suzhou-based biotech Alphamab Oncology (9966.HK) announced first patient dosing in a Phase II clinical study for cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immunosuppressive fusion protein KN019.
China-based firms Innovent Biologics Inc., (HKEX: 01801) and Shenogen Pharma Group Ltd, have struck a deal to collaborate on clinical development of a combination therapy for advanced cancers.
China’s Center for Drug Evaluation (CDE) released a Q&A style commentary on several issues related to biosimilars development, based on exchanges with companies during the development process.
China-based Sino Biopharmaceutical Ltd (HKEX.01177) announced the signing of a joint venture (JV) agreement between its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd, and Akeso Biopharma Inc​.
Recent news
Some good news for Wuhan amid dark times.
Mexico’s Ministry of Health (SSA) has announced it will update its treatment protocols for the 15 most common types of cancer in the country, as well as diabetes and hypertension.
According to industry insiders, 70% of the ARS 12 billion (USD 318 million) debt of Argentina’s health system with drug retailers comes from anti-cancer medicines.
China’s National Medical Products Administration (NMPA) has waved through two medical devices for marketing.
Chinese pharmaceutical firm China Medical System Holdings Ltd (HKEX.0867) announced a licensing deal with India-based Cadila Healthcare Ltd (Zydus Cadila) in relation to the latter’s ZYAN1 (desidustat).
A team of researchers at the University of Chile (UCH) is working or reprograming aged skin cells to obtain aged neurons that can be used to study the process and consequences of aging on the brain.
  • 1579591960083
  • Chile
  • R&D
China's National Health Commission (NHC) on Monday listed the pneumonia associated with the novel coronavirus (2019-nCoV), known as the Wuhan pneumonia, as a notifiable disease.
Analytics Snapshot